Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2071 to 2085 of 8314 results

  1. Infrared lasers for treating onychomycosis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. Intradiscal oxygen-ozone treatment of symptomatic lumbar disc herniation

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Transoral Endoscopic Thyroid/Parathyroid Vestibular Approach

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  4. Extra-vascular implantable cardioverter defibrillator (EVICD) for people with a defibrillator

    Awaiting development Reference number: GID-IPG10437 Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  5. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]

    In development Reference number: GID-TA11675 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Polycystic ovary syndrome: assessment and management

    In development Reference number: GID-NG10436 Expected publication date:  03 November 2026

    NICE guideline
    In development

  7. Artificial Intelligence in MRI for prostate cancer diagnosis

    Awaiting development Reference number: GID-HTE10089 Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  8. Ectopic pregnancy and miscarriage: diagnosis and initial management (update)

    In development Reference number: GID-NG10444 Expected publication date:  06 May 2026

    NICE guideline
    In development

  9. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy ID6575

    In development Reference number: GID-TA11742 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia ID6519

    In development Reference number: GID-TA11649 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

    In development Reference number: GID-TA10726 Expected publication date:  25 February 2026

    Technology appraisal guidance
    In development

  12. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]

    In development Reference number: GID-TA11254 Expected publication date:  04 March 2026

    Technology appraisal guidance
    In development

  13. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

    In development Reference number: GID-TA11340 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID6235

    In development Reference number: GID-TA11246 Expected publication date:  11 February 2026

    Technology appraisal guidance
    In development

  15. ID6610 Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901)

    In development Reference number: GID-TA11850 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development